Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 18Genitourinary 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Classical hematology 1Breast 1

Conditions

Ovarian Neoplasms 2Lung Neoplasms 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 39Gemcitabine 30Nivolumab 15Cetuximab 13Carboplatin 13Cyclophosphamide 12Cisplatin 12Irinotecan 10Docetaxel 10130-nm albumin-bound paclitaxel 10Trastuzumab 8Magnetic Resonance Spectroscopy 8fludarabine 7aldesleukin 7Paclitaxel 7Drug Therapy 7Bevacizumab 7Taxes 6Specimen Handling 6Fluorouracil 6Capecitabine 6Albumin-Bound Paclitaxel 6sargramostim 5Pemetrexed 5Oxaliplatin 5Ipilimumab 5spartalizumab 4durvalumab 4Standard of Care 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × dehydroftorafur × Thoracic × Clear all
NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

Phase 2 Recruiting
94 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡